Broadband reverse saturable absorption is systematically investigated via Z-scan, transient absorption spectrum (TAS). The excited state absorption and negative refraction of Orange IV are observed in the Z-scan experiment at 532 nm. Meanwhile, two-photon induced excited-state absorption and pure two-photon absorption are observed at 600 nm and 700 nm with the pulse width of 190 fs, respectively. An ultrafast broadband absorption in visible wavelength region is observed via TAS. The different nonlinear absorption mechanism at multiple wavelengths is discussed and interpreted from the results of TAS. In addition, the ultrafast dynamics of negative refraction in the excited state of Orange IV is investigated via degenerate phase object pump probe, from which the weak long-lived excited state is extracted. All studies indicate that Orange IV has the potential to be further optimized into a superior broadband reverse saturable absorption material and also has certain reference significance for the study of optical nonlinearity in organic molecules containing azobenzene groups.

The COVID-2019 disease caused by the SARS-CoV-2 virus (aka 2019-nCoV) has raised significant health concerns in China and worldwide. While novel drug discovery and vaccine studies are long, repurposing old drugs against the COVID-2019 epidemic can help identify treatments, with known preclinical, pharmacokinetic, pharmacodynamic, and toxicity profiles, which can rapidly enter Phase 3 or 4 or can be used directly in clinical settings. In this study, we presented a novel network based drug repurposing platform to identify potential drugs for the treatment of COVID-2019. We first analysed the genome sequence of SARS-CoV-2 and identified SARS as the closest disease, based on genome similarity between both causal viruses, followed by MERS and other human coronavirus diseases. Using our AutoSeed pipeline (text mining and database searches), we obtained 34 COVID-2019-related genes. Taking those genes as seeds, we automatically built a molecular network for which our module detection and drug prioritization algorithms identified 24 disease-related human pathways, five modules and finally suggested 78 drugs to repurpose. Following manual filtering based on clinical knowledge, we re-prioritized 30 potential repurposable drugs against COVID-2019 (including pseudoephedrine, andrographolide, chloroquine, abacavir, and thalidomide) . We hope that this data can provide critical insights into SARS-CoV-2 biology and help design rapid clinical trials of treatments against COVID-2019.